Cubist Systematic Strategies LLC Buys 249,121 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Cubist Systematic Strategies LLC lifted its stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 3,573.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 256,092 shares of the biotechnology company's stock after acquiring an additional 249,121 shares during the quarter. Cubist Systematic Strategies LLC owned 0.36% of Aclaris Therapeutics worth $635,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ACRS. ExodusPoint Capital Management LP bought a new position in Aclaris Therapeutics during the fourth quarter worth about $26,000. Invesco Ltd. bought a new position in shares of Aclaris Therapeutics in the fourth quarter worth about $28,000. Commonwealth Equity Services LLC bought a new position in shares of Aclaris Therapeutics during the fourth quarter valued at $36,000. Alpine Global Management LLC bought a new position in Aclaris Therapeutics during the fourth quarter worth $38,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Aclaris Therapeutics in the 4th quarter worth $82,000. 98.34% of the stock is owned by hedge funds and other institutional investors.

Aclaris Therapeutics Stock Performance

NASDAQ ACRS traded down $0.02 on Wednesday, reaching $1.34. The company's stock had a trading volume of 50,730 shares, compared to its average volume of 1,178,661. The stock has a market cap of $144.56 million, a PE ratio of -2.57 and a beta of 0.42. Aclaris Therapeutics, Inc. has a twelve month low of $0.95 and a twelve month high of $5.17. The firm's 50 day moving average is $1.35 and its two-hundred day moving average is $2.22.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.07. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. Equities research analysts anticipate that Aclaris Therapeutics, Inc. will post -0.82 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ACRS shares. HC Wainwright reaffirmed a "buy" rating and set a $16.00 target price (down previously from $20.00) on shares of Aclaris Therapeutics in a report on Wednesday, May 14th. Scotiabank lowered their price target on shares of Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating on the stock in a report on Friday, May 9th. StockNews.com downgraded shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, February 8th. Finally, Cantor Fitzgerald initiated coverage on shares of Aclaris Therapeutics in a report on Tuesday, March 18th. They issued an "overweight" rating on the stock. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Aclaris Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $10.00.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.